Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02276027 | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2020 |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT01798446 | A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus | completed | Phase 2 | 41 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01687673 | Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT00551070 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2020 | clinicaltrials |
| NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02093598 | POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus(POEM) | completed | Phase 2 | 10 | MedSIROTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03066427 | Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.(INMUNOSUN) | completed | Phase 2 | 23 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01264705 | Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer | completed | Phase 1 / Phase 2 | 47 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02658019 | Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | Lynn Feun, MDOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03380130 | A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC(NASIR-HCC) | completed | Phase 2 | 41 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00026104 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00114179 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01297244 | A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 105 | AVEO Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 27, 2020 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT00083941 | A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer | completed | Phase 2 | 25 | Oxford BioMedicaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00325507 | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma | completed | Phase 2 | 25 | Oxford BioMedicaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00113217 | Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 54 | Gynecologic Oncology GroupNETWORK | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01208103 | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00502307 | A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | completed | Phase 2 | 272 | AVEO Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 1, 2020 | clinicaltrials |
| NCT00094445 | Trial of Curcumin in Advanced Pancreatic Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT01935700 | Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma | completed | Phase 2 | 15 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT00668811 | Sutent Adjunctive Treatment of Differentiated Thyroid Cancer(IIT Sutent) | completed | Phase 2 | 23 | Medstar Health Research InstituteOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01222689 | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03140553 | TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer(neoCARH) | completed | Phase 2 | 140 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT02560779 | Trial of TRC105 and Sorafenib in Patients With HCC | completed | Phase 1 / Phase 2 | 27 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jul 17, 2020 | clinicaltrials |
| NCT02362958 | A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | completed | Phase 2 | 159 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT04462445 | Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb(PIPELINE) | completed | Phase 2 | 25 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Jul 10, 2020 | clinicaltrials |
| NCT00853372 | AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | completed | Phase 2 | 85 | AmgenINDUSTRY | 0 | Jul 1, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT02514551 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | completed | Phase 2 | 245 | Eli Lilly and CompanyINDUSTRY | 11 | Jun 17, 2020 | clinicaltrials |
| NCT03575806 | Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | completed | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02187302 | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | completed | Phase 2 | 115 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT01896869 | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 83 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT01510119 | Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT01775501 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | completed | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02061332 | DC Vaccine for Patients With Ductal Carcinoma In Situ(DCIS6) | completed | Phase 1 / Phase 2 | 58 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT02716766 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03578874 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | completed | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT01507168 | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 185 | Hoffmann-La RocheINDUSTRY | 13 | Apr 3, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Dec 19, 2020source: clinicaltrials